Table 4.
Characteristics of smokers among 8,383 survivors (Hypothesis 2a)
| Number of smokers (%)b |
|||
| Number of survivors | Ever-smokers | Current smokers | |
| Total subsample | 8,383 | 2,709 (32.3) | 1,345 (16.0) |
| Sex | |||
| Female | 4,252 | 1,283 (30.2) | 623 (14.7) |
| Male | 4,131 | 1,426 (34.5) | 722 (17.5) |
| Race/ethnicity c | |||
| White, non-Hispanic | 7,178 | 2,358 (32.9) | 1,164 (16.2) |
| Non-White | 1,172 | 344 (29.4) | 176 (15.0) |
| Age at diagnosis (years) | |||
| 0–2 | 1,862 | 541 (29.1) | 304 (16.3) |
| 3–5 | 1,873 | 577 (30.8) | 328 (17.5) |
| 6–9 | 1,370 | 441 (32.2) | 228 (16.6) |
| 10–15 | 2,144 | 713 (33.3) | 326 (15.2) |
| 16–20 | 1,134 | 437 (38.5) | 159 (14.0) |
| Age at 2003FU (years) | |||
| 18–24 | 1,722 | 478 (27.8) | 313 (18.2) |
| 25–29 | 1,767 | 598 (33.8) | 304 (17.2) |
| 30–34 | 1,946 | 587 (30.2) | 293 (15.1) |
| 35–39 | 1,553 | 499 (32.1) | 235 (15.1) |
| 40–54 | 1,395 | 547 (39.2) | 200 (14.3) |
| Cancer diagnosis | |||
| Bone cancer | 738 | 259 (35.1) | 122 (16.5) |
| CNS | 887 | 250 (28.2) | 124 (14.0) |
| HD | 1,142 | 436 (38.2) | 162 (14.2) |
| Kidney (Wilms) | 792 | 272 (34.3) | 144 (18.2) |
| Leukemia | 2,860 | 830 (29.0) | 470 (16.4) |
| Non-Hodgkin’s lymphoma | 652 | 228 (35.0) | 114 (17.5) |
| Neuroblastoma | 549 | 189 (34.4) | 101 (18.4) |
| Soft tissue sarcoma | 763 | 245 (32.1) | 108 (14.2) |
| Cancer treatmentd | |||
| CRT | 2,315 | 573 (24.8) | 337 (14.6) |
| IT MTX | 2,838 | 815 (28.7) | 457 (16.1) |
| HD Ara-C | 1,185 | 322 (27.2) | 158 (13.3) |
| HD MTX | 810 | 234 (28.9) | 116 (14.3) |
| Spinal radiation | 575 | 136 (23.7) | 82 (14.3) |
| Brain surgery | 797 | 221 (27.7) | 107 (13.4) |
| Dexamethasone | 574 | 151 (26.3) | 73 (12.7) |
| EF | |||
| Task efficiency problem | |||
| No | 4,562 | 1,372 (30.1) | 614 (13.5) |
| Yes | 1,709 | 559 (32.7) | 299 (17.5) |
| Organization problem | |||
| No | 5,129 | 1,564 (30.5) | 715 (13.9) |
| Yes | 1,142 | 367 (32.1) | 198 (17.3) |
| Emotional regulation problem | |||
| No | 4,759 | 1,376 (28.9) | 609 (12.8) |
| Yes | 1,512 | 555 (36.7) | 304 (20.1) |
| Memory problem | |||
| No | 5,061 | 1,494 (29.5) | 687 (13.6) |
| Yes | 1,210 | 437 (36.1) | 226 (18.7) |
Note. 2003FU = 2003 follow-up; CNS = central nervous system; CRT = cranial radiation therapy; EF = executive functioning; HD = high dose (≥1,000 mg/m2); IT = intrathecal; MTX = methotrexate.
a
Study population defined as those ≥18 years of age at 2003FU (n = 8,383).
b
Number (%) = participants in the row who are ever- or current smokers.
c
Missing information: race (n = 33) and EF (n = 2,112).
d
Some survivors are represented in more than one treatment category. Treatment information is missing for survivors without medical chart abstractions (n = 706).